Program
Crovalimab
Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Anemia, Sickle Cell · Antiphospholipid Syndrome · Guillain-Barre Syndrome, led by Hoffmann-La Roche.
Furthest: phase 3, since Jun 3, 202010 company-led studies, 5 open or runningNext primary completion: Apr 18, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 105 open or running | phase 3since Jun 3, 2020 | Nov 1, 2016 | Apr 18, 2027phase 3 · NCT04432584 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 1, 2016First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT03157635 · 59 enrolled · France, Germany, Hungary and more
- Jun 3, 20202 phase 3 studies in Hemoglobinuria, ParoxysmalNCT04434092, NCT04432584
- Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalNCT04654468 · 51 enrolled · China
- Apr 23, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04861259 · 83 enrolled · United States, Belgium, Brazil and more
- Jun 2, 2021Phase 1 study in Anemia, Sickle CellNCT04912869 · 30 enrolled · United States, Brazil, France and more
- Jul 6, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04958265 · 41 enrolled · United States, Belgium, Brazil and more
- Sep 20, 2021Phase 2 study in Anemia, Sickle CellNCT05075824 · 95 enrolled · United States, Brazil, France and more
- Aug 8, 2022Phase 3 study in Guillain-Barre SyndromeNCT05494619
- Sep 11, 2025Phase 2 study in Antiphospholipid SyndromeNCT07172022
Ahead
- Apr 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04432584
TargetBeta
C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07172022Antiphospholipid Syndrome | 2 | Withdrawn | Mar 11, 2030 | 0 |
| NCT05494619Guillain-Barre Syndrome | 3 | Withdrawn | Mar 19, 2026 | 0 |
| NCT05075824Anemia, Sickle Cell · United States, Brazil, France and more | 2 | Completed | Jun 11, 2025 | 95 |
| NCT04958265Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jul 4, 2025 | 41 |
| NCT04912869Anemia, Sickle Cell · United States, Brazil, France and more | 1 | Completed | Dec 23, 2024 | 30 |
| NCT04861259Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Oct 9, 2025 | 83 |
| NCT04654468Hemoglobinuria, Paroxysmal · China | 3 | Active, not recruiting | Feb 10, 2022 | 51 |
| NCT04434092Hemoglobinuria, Paroxysmal · Argentina, Brazil, China and more | 3 | Active, not recruiting | Nov 16, 2022 | 210 |
| NCT04432584Hemoglobinuria, Paroxysmal · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Apr 18, 2027 | 190 |
| NCT03157635Hemoglobinuria, Paroxysmal · France, Germany, Hungary and more | 2 | Completed | Aug 13, 2026 | 59 |
How it is read
Names in the registry
- “Crovalimab”, 10 entries
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 4 studies
- Atypical Hemolytic Uremic Syndrome, 2 studies
- Anemia, Sickle Cell, 2 studies
- Antiphospholipid Syndrome, 1 study
- Guillain-Barre Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.